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Microencapsulation with alginate/
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phage therapy
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Daniel Maspoch2,3 & Montserrat Llagostera1
Bacteriophages are promising therapeutic agents that can be applied to different stages of the 
commercial food chain. In this sense, bacteriophages can be orally administered to farm animals to 
protect them against intestinal pathogens. However, the low pH of the stomach, the activities of bile 
and intestinal tract enzymes limit the efficacy of the phages. This study demonstrates the utility of 
an alginate/CaCO3 encapsulation method suitable for bacteriophages with different morphologies 
and to yield encapsulation efficacies of ~100%. For the first time, a cocktail of three alginate/CaCO3-
encapsulated bacteriophages was administered as oral therapy to commercial broilers infected 
with Salmonella under farm-like conditions. Encapsulation protects the bacteriophages against 
their destruction by the gastric juice. Phage release from capsules incubated in simulated intestinal 
fluid was also demonstrated, whereas encapsulation ensured sufficient intestinal retention of the 
phages. Moreover, the small size of the capsules (125–150 μm) enables their use in oral therapy 
and other applications in phage therapy. This study evidenced that a cocktail of the three alginate/
CaCO3-encapsulated bacteriophages had a greater and more durable efficacy than a cocktail of the 
corresponding non-encapsulated phages in as therapy in broilers against Salmonella, one of the most 
common foodborne pathogen.
In farm animals and in aquaculture, antibiotics have been used not only in the treatment of infections but also as 
growth promoters. However, this intensive use of antibiotics has given rise to the emergence of resistant strains of 
commensal and pathogenic microorganisms that are able to spread to humans, either directly through the food 
chain or indirectly via the environmental pollution caused by farm effluents1. The European Food Safety Authority 
(EFSA) has played an essential role in monitoring and detecting the risks posed by the emergence of multi-drug 
resistant bacteria within the food industry2. As an alternative to the use of antibiotics, bacteriophages are promis-
ing therapeutic agents due to their ubiquity, high specificity, replication capacity inside their host, and their ease of 
isolation and production. The use of bacteriophage-based products in different stages of the food chain3,4 as well 
as in humans5,6 and animals4,7 via different routes of administration has been investigated. However, a challenge 
of oral phage therapy is that the phages must overcome numerous adverse conditions, including the low pH of the 
stomach, the activity of bile, and the activities of enzymes in the digestive tract8–10 and also their short residence 
time in the digestive tract11. In addition, when used in food protection bacteriophages may interact with food 
components and be exposed to unfavourable conditions or their stability during food processing and storage may 
be compromised. These problems can be successfully addressed by encapsulation, which would be able to protect 
bacteriophages under similar potentially deleterious conditions. Among the many diverse biomaterials used for 
phage encapsulation are cellulose, liposomes, alginate, whey proteins, and gelatin, which have been applied using 
different techniques12,13. Alginate is one of the most common biomaterials used in microencapsulation, including 
that of probiotics14,15 and, as recently shown, bacteriophages. The latter was achieved using alginate either alone 
or in combination with other components, in which wet capsules ranging in size from 310 μ m to almost 1 mm 
were obtained8,10,16–18. Alginate, a linear copolymer containing blocks of (1, 4)-linked β -D-mannuronate and 
α -L-guluronate residues, is of low toxicity and immunogenicity and thus regarded as a biocompatible material19. 
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When used as a hydrogel in biomedical applications19, alginate is combined with ionic cross-linking agents, such 
as divalent cations. In oral bacteriophage therapy, it protects the phage by shrinking at low pH values, dissolving 
at high pH values8, and participating in mucoadhesive interactions with gastrointestinal mucus20. These results 
were obtained from in vitro studies that examined the interactions of alginate-encapsulated bacteriophages with 
simulated gastric and intestinal fluids. By contrast, the use of alginate-encapsulated bacteriophages in oral phage 
therapy has been tested in only a few in vivo experiments involving Salmonella in pigs21,22. To our knowledge, the 
present study is the first in which wet bacteriophage-containing alginate/CaCO3 microcapsules < 150 μ m in size 
were obtained and then used as oral therapy to protect broiler chickens against Salmonella infection, under con-
ditions mimicking those of poultry production farms. In particular, a cocktail composed by three virulent bacte-
riophages (UAB_Phi20, UAB_Phi78, and UAB_Phi87) was prepared according to previous promising results of 
phage-therapy studies11,23,24.
Results
Characterization of alginate/CaCO3-encapsulated phages. The three bacteriophages were encapsu-
lated separately into alginate/CaCO3 and their properties then examined. The mean size of alginate-encapsulated 
UAB_Phi20, UAB_Phi78, and UAB_Phi87 as determined by laser diffraction was 124 ± 9 μ m, 141 ± 16 μ m, and 
149 ± 6 μ m, respectively. The alginate/CaCO3-encapsulated bacteriophages were then characterized by labelling 
the phage and the alginate with SYBR gold and DAPI, respectively. The 3D spatially superimposed SYBR-gold 
(green) and DAPI- (blue) fluorescence intensities are shown in Fig. 1. The images show that all of the phages 
were properly encapsulated in the capsules. This was confirmed by the encapsulation yields of 98.0% ± 1.5 for 
UAB_Phi20, 99.0% ± 0.1 for UAB_Phi78, and 99.0% ± 0.7 for UAB_Phi87 (Table 1).
Figure 1. 3D confocal microscopy images of SYBR-gold-labelled UAB_Phi20 (a), UAB_Phi78 (b), and UAB_
Phi87 (c) (green) encapsulated in DAPI-labelled alginate capsules (blue). 3D images of the capsules are shown 
on the left (1), and the corresponding cross-sectional images in the middle (2) and on the right (3). Scale bars, 
30 μ m.
Bacteriophage Fresha
Stored at 4 °Ca
Three months Six months
UAB_Phi20 98.0 ± 1.5 84.0 ± 0.7 74.0 ± 8.6
UAB_Phi78 99.0 ± 0.1 89.0 ± 2.3 73.0 ± 4.2
UAB_Phi87 99.0 ± 0.7 92.0 ± 5.9 94.0 ± 5.2
Table 1.  Percentage (%) of alginate/CaCO3-encapsulated phages after their storage at 4 °C for 6 months. 
aEach value represents the average from three independent experiments ± standard deviation.
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The stability of the alginate/CaCO3-encapsulated phages was determined by storing freshly encapsulated 
phages at 4 °C for 6 months and then again measuring the percentage of encapsulated phages. As shown in Table 1, 
for cold-stored UAB_Phi20 and UAB_Phi78 there was only a slight decrease in the encapsulation percentage 
compared to the values of freshly encapsulated phages, whereas for cold-stored encapsulated UAB_Phi87 phage 
there was no loss of encapsulated phage. Similarly, no decrease in the encapsulation percentage was observed after 
maintaining the alginate/CaCO3-encapsulated phages two weeks at room temperature (data not shown).
Stability of the encapsulated bacteriophages in simulated gastric fluid. The acid stability of the 
alginate/CaCO3-encapsulated phages was tested by incubating them in simulated gastric fluid (SGF) (pH 2.8) for 
60 min. These phages proved to be much more stable under acidic conditions than their non-encapsulated coun-
terparts (Fig. 2) (p < 0.05). Thus, titre losses of phage UAB_Phi78 and phage UAB_Phi87 were 3.1 and 2.4 log10 
after 30 min and 2.9 and 3.5 log10 after 60 min of incubation, respectively. Remarkably, there was no reduction in 
the titre of UAB_Phi20 after 60-min incubation with SGF.
Encapsulated phage release by simulated intestinal fluid. The kinetics of phage release from alg-
inate/CaCO3 capsules incubated for up to 40 min with simulated intestinal fluid (SIF) was also assessed. After 
20 min of incubation in SIF, the percentage of UAB_Phi20, UAB_Phi78, and UAB_Phi87 release was 79.0% ± 9.1, 
60.7% ± 2.4, and 95.6% ± 7.6, respectively (Fig. 3). After 40 min, release was nearly complete for all phages 
(97.7% ± 18.6, 88.4% ± 7.6, and 100.0% ± 20.8, respectively; Fig. 3).
In vivo retention of bacteriophage in the chicken caecum. Previously to do the studies of retention 
and phage therapy in chicken, we observed that alginate/CaCO3 capsules without phages were innocuous in a 
mouse model (data not shown).
The caecal residence time of a cocktail of the three non-encapsulated and alginate/CaCO3-encapsulated 
phages differed significantly at all three time points tested. Thus, after 2 h the encapsulated phages were retained 
Figure 2. Stability of the non-encapsulated (light gray bars) and alginate/CaCO3-encapsulated (dark gray 
bars) bacteriophages in simulated gastric fluid. (a) UAB_Phi20, (b) UAB_Phi78, and (c) UAB_Phi87. Each 
value is the average of six independent experiments ± standard deviation. *p < 0.05.
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in 95.2% of the chickens and the non-encapsulated phages in 57.1% (p < 0.05; Fig. 4). After 48 and 72 h the differ-
ences were still significant (p < 0.001): 95.2% vs. 38.1%, and 71.4% vs. 9.5%, respectively (Fig. 4).
Bacteriophage therapy against Salmonella infection in broiler chickens. Cocktails prepared from 
non-encapsulated and alginate/CaCO3-encapsulated phages differed in their long-term efficacies in protecting 
commercial broiler chickens against Salmonella infection, as determined based on the caecal Salmonella concen-
tration (Table 2). Thus, within the first 6 days post-infection, reductions in the Salmonella concentration in the 
two treated groups were nearly the same and both were significant compared to the control untreated chickens 
(p < 0.001). However, on day 1 post-infection, a greater reduction of Salmonella counts was obtained with the 
non-encapsulated than the encapsulated phages (p < 0.05). The reduction in the Salmonella concentration in 
chickens administered the cocktail of non-encapsulated phages was significant until day 8, the first day after treat-
ment cessation (1.5 log10 reduction; p < 0.05). By contrast, the protection achieved with the cocktail of alginate/
CaCO3-encapsulated phages was significant vs. the control from de beginning until day 15 post-infection (days 
8 and 10: p < 0.001; day 15: p < 0.05), with reductions in Salmonella counts on days 8, 10, and 15, of 3.6, 3.4, and 
1.7 log10, respectively. A further comparison of the two phage treatments showed that the reduction achieved 
with the cocktail of alginate/CaCO3-encapsulated phages was significantly greater than that obtained with the 
non-encapsulated phages from day 8 until the end of the experiment (days 8 and 10: p > 0.001; day 15: p > 0.05; 
Table 2). It must be mentioned that we did not find any bacteria isolated from phage-treated groups to be resistant 
against the three phages of the cocktail administered (manuscript in preparation).
Bacteriophage concentrations remained stable throughout the experiment and were slightly higher in the 
non-encapsulated (4.2–4.4 log10 pfu/g of caecum) than in the alginate-encapsulated (3.8–3.0 log10 pfu/g of cae-
cum) group from day 1 to day 10 post-infection (Table 3). However, the concentration in the caecum of the 
non-encapsulated group was significantly greater (5.1 log10 pfu/g; p < 0.001) than in the alginate-encapsulated 
Figure 3. In vitro release of alginate/CaCO3-encapsulated UAB_Phi20 (○), UAB_Phi78 (▪), and 
UAB_Phi87 (◊) incubated in simulated intestinal fluid. Each value is the average of three independent 
experiments ± standard deviation.
Figure 4. Persistence of the non-encapsulated (light gray) and alginate/CaCO3-encapsulated (dark gray) 
bacteriophages in the broiler caecum. *p < 0.05, ***p < 0.001.
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(0.2 log10 pfu/g) on day 15. It must be noted that the presence of the three bacteriophages in caecum samples 
could be demonstrated due to their different plaque morphology (Fig. 5).
Discussion
Methods allowing the stable and controlled delivery of bacteriophages are of great value in phage therapy. One 
such method is encapsulation, which in farm animals protects orally administered bacteriophages from the harsh 
environment of the stomach and facilitates their retention during passage through the intestinal tract to ensure a 
successful therapeutic effect24–26. By maintaining bacteriophage stability, micro- or nano-encapsulation enables 
not only their oral administration through feed or water but also their administration in other forms, such as 
inhalation, thereby assuring an adequate dose of the therapeutic phage. Furthermore, encapsulation can over-
come other problems related to the application of bacteriophages in food industry processes. The materials used 
in bacteriophage encapsulation have been examined in several studies12,13 and include alginate, alone or in com-
bination with other materials8,10,16–18. However, few studies have described the in vivo use of alginate-encapsulated 
bacteriophages21,22,27. Thus, our study is the first to test a cocktail of three alginate/CaCO3-encapsulated virulent 
bacteriophages (UAB_Phi20, UAB_Phi78, and UAB_Phi87)11,23 as oral therapy in Salmonella-infected poultry 
under farm-like conditions. Phages prepared according to this method were shown to be effective in protecting 
broilers against infection for up to 15 days.
The encapsulation methodology described herein allows the encapsulation of bacteriophages with different 
morphologies, without jeopardizing infectivity. The encapsulation efficiency values obtained in this study were 
~99%, similar to the percentages reported by other authors8,10,16,17,25. Moreover, the alginate/CaCO3 encapsulated 
bacteriophages showed excellent stability when stored at 4 °C for 6 months, with minor losses determined only 
for UAB_Phi20 and UAB_Phi78. Also, the encapsulated phages were stable at room temperature at least for two 
weeks, period of time that is sufficient for the administration to animals in drinking water.
Another promising feature of the alginate/CaCO3 microcapsules was their size (124–149 μ m), which was 
almost ten times smaller than other types of capsules described in the literature8,10,16,17,25 and facilitated their 
potential commercial applications. All this is the result of various systematic studies aimed at optimizing the algi-
nate concentration (1.8%) and the posterior curing time of the capsules in the bath of CaCl2 (90 min).
Phages orally administered to broilers must withstand the low pH of the stomach contents of the chickens, 
which is typically in the range of 2.1–3.628,29. Under acidic conditions, the alginate/CaCO3-encapsulated phages 
proved to be much more stable than their non-encapsulated counterparts (Fig. 2) (p < 0.05), resulting in titre 
losses after 60 min of incubation in SGF that were around 5 times lower for phages UAB_Phi78 and UAB_Phi87. 
There was no loss of encapsulated UAB_Phi20. It is reported that the incorporation of CaCO3 slows the gela-
tion rate of alginate capsules, whereas CO3− ions dissociated from CaCO3 diffuse into the medium and slightly 
Day post-infection
Salmonella concentration in caecum (log10 cfu/g)a
Control group Encapsulated group Non-encapsulated group
1 5.8 ± 0.7 4.5 ± 1.4b 2.9 ± 2.3b,c
3 6.6 ± 0.5 4.0 ± 1.5b 3.3 ± 2.7b
6 6.9 ± 0.8 3.8 ± 2.2b 4.1 ± 2.1b
8 6.7 ± 0.5 3.1 ± 2.5b,c 5.2 ± 2.2b,d
10 6.4 ± 1.0 3.0 ± 0.9b,c 5.7 ± 1.9d
15 5.2 ± 1.3 3.5 ± 2.1b,c 6.3 ± 1.0d
Table 2.  Salmonella concentration in the caeca of broilers treated with alginate/CaCO3-encapsulated and 
non-encapsulated bacteriophages. aEach value is the average from 14 caecum samples ± standard deviation. 
bStatistical significance between the control and each treated group (p < 0.001 at days 1 to 6; for p < 0.001 at 
days 8 and 10 for the encapsulated group, and p < 0.05 at day 8 for non-encapsulated group and at day 15 for 
encapsulated group). cStatistical significance between the two treated groups p < 0.05 at days 1 and 8, and 
p < 0.001 on days 10 and 15. dStatistical significance of the increase of Salmonella concentration at days 8 and 10 
(p < 0.05), and on day 15 (p < 0.001), with respect day 1 post-infection.
Days post-infection
Bacteriophage concentration in caecum (log10 pfu/g)a
Encapsulated group Non-encapsulated group
1 3.8 ± 1.0 4.2 ± 0.6
3 3.5 ± 1.0 4.7 ± 1.7
6 3.6 ± 1.4 4.0 ± 0.8
8 3.8 ± 1.2 4.2 ± 2.1
10 3.0 ± 1.7 4.4 ± 2.7
15 0.2 ± 0.6 5.1 ± 2.2b
Table 3.  Bacteriophage concentrations in the caeca of broilers treated with alginate/CaCO3-encapsulated 
and non-encapsulated bacteriophages. aEach value is the average from 14 caecum samples ± standard 
deviation. bStatistical significance between the encapsulated and non-encapsulated groups (p < 0.001).
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increase the pH as a role of antacid, thus protecting the bacteriophages10,19. Our results are in accordance with 
those obtained by10, who also reported a good protection effect on the bacteriophage K once encapsulated in a 
mixture of alginate/CaCO3 capsules of a diameter of ~900 μ m. However, in our case, this protection effect was 
achieved even lowering the size of the capsules down to ~150 μ m of size.
Another important feature of alginate/CaCO3-encapsulated bacteriophages is their release in the animal intes-
tine, where the host pathogen is located. In this study, the three phages exhibited slightly different in vitro release 
kinetics. Thus, whereas almost a complete release of bacteriophage UAB_Phi87 was observed after 20 min of incu-
bation in SIF, UAB_Phi20 and UAB_Phi78 were released more slowly, being this release completed after 40 min 
(Fig. 3). A potential explanation of the faster release of UAB_Phi87 is that this phage has a larger size than the 
other two phages, which could provoke the formation of alginate capsules with a lower reticular or cross-linked 
structure and therefore, a faster release of the encapsulated phages. In addition, a comparison of our release 
results with those of other authors is difficult, since the size and composition of the microcapsules, the composi-
tion of the SIF and the incubation conditions (pH and temperature) differed8,10,16,18.
However, bacteriophage release kinetics will undoubtedly differ in vivo. Currently, whether phages adhere to 
the intestinal epithelium30 or their presence becomes insignificant in the absence of the bacterial host is unclear11,31. 
The mucoadhesive properties of alginate32 could prolong the presence and the effect of bacteriophages used in oral 
phage therapy. Our in vivo results of residence time demonstrate that alginate/CaCO3 encapsulation enables the sig-
nificant intestinal retention of the bacteriophages even in the absence of host. Thus, bacteriophages were detected in 
71.4% of the chickens 72 h after oral administration of a single dose of the cocktail of encapsulated bacteriophages 
compared to 9.5% of the chickens treated with the non-encapsulated phages (p < 0.001). The percentage obtained 
with the alginate/CaCO3 capsules was better than obtained in a previous in vivo study of liposome-encapsulated 
bacteriophages24, perhaps due to the higher encapsulation efficiency achieved with the former.
Figure 5. Plaque morphologies of UAB_Phi20 (a), UAB_Phi78 (b), UAB_Phi87 (c), and the cocktail of the 
three bacteriophages (d) in double agar layer plates. Arrows indicate the different plaque morphology of each 
bacteriophage.
www.nature.com/scientificreports/
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The cocktail composed of the three alginate/CaCO3-encapsulated bacteriophages demonstrated long-term 
efficacy when used in commercial broilers chickens infected with Salmonella, mimicking real farm conditions. 
Colonization by Salmonella was effectively reduced by administering a phage cocktail composed of alginate/
CaCO3-encapsulated bacteriophages to the poultry 1 day prior to infection with the bacterium and for an addi-
tional 7 days during treatment. Moreover, the protective effect was significantly maintained for 1 week after 
treatment was stopped (on day 15-post infection). Differently, the non-encapsulated bacteriophages quickly 
loosed their effect once the treatment was stopped. During the first 6 days post-infection, the encapsulated and 
non-encapsulated cocktails were of similar efficacies, with maximum reductions in Salmonella counts of 3.1 and 
2.8 log10, respectively. Only on the first day of treatment was the non-encapsulate cocktail significantly more 
effective (reduction of 2.9 vs. 1.3 log10; p < 0.05; Table 2). This may have reflected the additional time required for 
the encapsulated phages to accumulate to an effective therapeutic concentration following their release. Then, 
it is likely that the phage release in vivo would be slower than in vitro SIF studies. However, the effect of the 
non-encapsulated cocktail was abolished 1 day after the cessation of treatment (day 7 post-infection) whereas the 
encapsulated cocktail maintained its effectiveness until the end of the experiment.
This is the first study to report the use of alginate/CaCO3-encapsulated bacteriophages as an in vivo oral 
therapy against Salmonella infections in poultry. While our results are similar to those achieved with liposome 
encapsulation24, preparation of the alginate/CaCO3 capsules is simpler and provides much higher encapsulation 
rates. Although treatment with the alginate/CaCO3 cocktail did not remove Salmonella totally, the concentration 
of Salmonella used in the experimental poultry infection was very high (~6 log10/g of caecum). Further studies 
should seek to ascertain the threshold Salmonella concentration in poultry farming and if the encapsulated cock-
tail could eliminate Salmonella from the chickens completely in those conditions.
Another important aspect in the success of phage therapy is the relationship between the phages and their 
bacterial hosts. According to the literature on bacteriophage-bacterial dynamics in vitro, the number of phage 
increases only when the cell density is sufficient, so that the probability of an encounter between the bacteri-
ophages and the bacteria and the subsequent infection of the latter exceeds the probability of phage death33. 
Therefore, the success of phage therapy is largely determined by the relationship between the concentration of the 
bacteriophages and that of their bacterial host34. However, the in vivo dynamics are presumably much more com-
plex because multiple external factors (e.g., rapid clearance of the bacteriophages by passive/active host immunity, 
spatial refuges, and intestinal mucous) influence treatment success35.
In our in vivo study, the dynamics of the non-encapsulated and encapsulated bacteriophages in controlling 
Salmonella differed which agree with a previous study performed by us with liposome-encapsulated bacterio-
phages24. Thus, with the daily administration of non-encapsulated bacteriophages, their uptake together with 
the new phage progeny produced in the intestinal tract led to a marked decrease in the Salmonella concentration 
(~50%) 1 day post-infection. Thereafter, until almost day 8 post-infection, the Salmonella concentration increased 
slightly but with significant therapeutic effect. Once the phage uptake was stopped, the equilibrium between 
phages and bacteria was disrupted and the Salmonella concentration increased significantly with respect to day 1 
post-infection (days 8 and 10, p < 0.05; day 15 post-infection, p < 0.001; Table 2). The requirement for continuous 
administration of bacteriophages along the time to achieve a low population of Samonella has also been suggested 
by other authors11,36. Several factors as partial emergence of bacteriophage-resistant Salmonella, bacterial pheno-
typic changes, physical refuges or slow growth rate of bacterial cells could explain this fact35,36. By contrast, when 
the encapsulated bacteriophage cocktail was administered, the Salmonella concentration decreased gradually 
during all the experiment, regardless of whether treatment was ongoing or had stopped. Therefore, the encapsu-
lation of bacteriophages abolished the need for a continuous treatment to achieve a low bacterial concentration. 
In this case, the mucoadhesiveness of the capsules and the release kinetics of the bacteriophages from them must 
be the most important features for this effect. It is remarkable that when the bacteriophage uptake was stopped 
the bacteriophage concentration remained nearly constant (Table 3) in both treatments, but the Salmonella con-
centration in the gut was higher in the non-encapsulated bacteriophage treatment than in encapsulated one. At 
this respect, it has been proposed that there is a threshold density of bacteria that must be present in order for 
the bacteriophage concentration to increase33. Further works are needed to identify the in vivo mechanism(s) 
underlying this fact.
In summary, this study demonstrated the utility of a simple, efficient, and inexpensive encapsulation method 
that can be used with bacteriophages of different morphologies. The small size of the resulting microcapsules 
(124–149 μ m) enables their use in diverse applications in phage therapy. Moreover, alginate/CaCO3 encapsu-
lation confers excellent protection against the deleterious effects of gastric juice and promotes greater intestinal 
retention of the bacteriophages. The results presented here, together with those from our previous investigation 
of liposome-encapsulated bacteriophages24, show that encapsulation is important for a prolonged and successful 
oral phage therapy in commercial broilers infected with Salmonella.
Methods
Bacterial strains and growth conditions. Phages UAB_Phi20, UAB_Phi78, and UAB_Phi87 were previ-
ously obtained by us from chicken and pig farms11,23. All three bacteriophages belong to the Caudovirales order. 
UAB_Phi20 and UAB_Phi78 bacteriophages are members of the Podoviridae family with icosahedral heads 
(60 ± 1.5 nm and 66 ± 1.7, respectively) and short tails (13–14 nm) whereas UAB_Phi87 has also an icosahe-
dral head (68 ± 2.7 nm) but a long contractile tail (114 ± 4.3 nm) and derives from the Myoviridae family11. The 
genomic features of the three bacteriophages have been recently published37. The bacteriophages were propagated 
in Salmonella Typhimurium LB5000 (SGSC181; University of Calgary). Broiler chickens were colonized with 
S. Typhimurium ATCC 14028 RifR. All bacterial strains were grown in Luria-Bertani (LB) broth or on LB agar 
plates for 18 h at 37 °C. S. Typhimurium ATCC 14028 RifR viable counts were obtained after incubating the 
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bacterium, plated on xylose-lysine-deoxycholate (XLD) plates (Laboratorios Conda, Spain) supplemented with 
rifampin (75 μ g/ml), at 37 °C for 18 h.
In vitro multiplication of bacteriophages. High-titer (1 × 1011–1 × 1012 pfu/ml in 10 mM MgSO4) 
lysates were obtained from bacteriophages propagated in S. Typhimurium strain LB5000 (SGSC181; University 
of Calgary) and subjected to ultracentrifugation at 51,000 × g for 2 h (OptimaTM L-80; Beckman, CA, USA), as 
previously described24. The phage titre was determined by plating serial dilutions (1:10) onto LB plates using the 
double agar layer method38.
Bacteriophage encapsulation with alginate/CaCO3. Encapsulation of the phages using alginate/
CaCO3 was carried out followed a previously described protocol with slight modifications10. Briefly, 500 mg of 
CaCO3 (1%) and 900 mg of alginate (1.8%) were added to 50 ml of each bacteriophage suspension in 10 mM 
MgSO4 at a concentration of 1 × 1011 pfu/ml. This mixture was stirred overnight to allow its proper homogeniza-
tion and then pumped at a rate of 1.5 ml/min into a bath containing 150 ml of 1.8% CaCl2 using the ViscoMistTM 
Air AtomiZing spray nozzle (inner diameter: 381 μ m; Lechler Inc., St. Charles, IL) under a continuous flow of 
nitrogen at a pressure of 3 bars. The gelled capsules were left to harden in the bath for 90 min with slow stirring 
and then centrifuged at 469 × g for 5 min. The resulting pellet was washed thrice with 10 mM MgSO4 and resus-
pended in 10 mM MgSO4 at a final volume of 50 ml.
Particle size distributions were determined by granulometric assays based on laser diffraction (Mastersizer 
2000, Malvern Instruments, UK), which was appropriate because of the micrometric size of the encapsulated 
phages. Laser diffraction is a well-established technique to determine particle size distributions covered by 
ISO13320 (2009)39, which measures the angular variation in intensity of light scattered as a laser beam passes 
through a dispersed particulate sample. The angular scattering intensity data is then analyzed to calculate the size 
of the particles responsible for creating the scattering pattern, using the Mie theory of light scattering. The mean 
particle size is reported as a volume equivalent sphere diameter and expressed in terms of the “volume weighted 
mean”, as the = ∑
∑
D[4, 3] 4
3
d
d
, where the diameter (d) has d4 dependence and the number of particles is not inher-
ent in the formulae. The D[4, 3] value was calculated using an algorithm from the Mastersizer Software. The 
undiluted capsules were measured directly after encapsulation and the D[4, 3] value is the media of three different 
measurements.
The encapsulation efficiency (EE) of the phages was calculated as EE (%) = 100 − (Cfree/Ctotal) × 100, where 
Ctotal is the concentration of all bacteriophages and Cfree the concentration of free phages24. To determine Ctotal, 
the product of the phage encapsulation was titrated directly. Because divalent ions are essential for the stability 
of the alginate capsules, degradation of the plated capsules may occur due to the sequestration of divalent ions 
during gelling of the double agar layer. To quantify Cfree, 0.5 ml of the encapsulation product was filtered through 
a 0.22-μ m PES filter syringe to retain the encapsulated phages. The eluted volume was then titered. The stability 
of the alginate-encapsulated phages at 4 °C was tested for 6 months using the above-described method for EE 
determination.
Microscopy. The phages were labeled with SYBR gold (Molecular Probes, OR, USA) as previously described24, 
and encapsulated as described above, but with the addition of 4′ ,6-diamidino-2′ -phenylindole dihydrochloride 
(DAPI)-labeled alginate to the mixture to a final volume of 10%. Alginate labeling was performed as previously 
described, but using DAPI rather than fluoresceinamine40. Samples of 30 μ l were observed using a Leica TCS SP5 
confocal microscope (Leica Microsystems, Germany) but without the resonance scanning mode, as the capsules 
were large enough to reduce Brownian motion.
Bacteriophage stability in simulated gastric fluid. The stability of the encapsulated phages in SGF 
(pH 2.8), consisting of 3 mg pepsin (Sigma-Aldrich, MO, USA)/ml in 0.85% NaCl, was tested as previously 
described24. However, in this study, the solution exhibited a buffering effect till a pH value of 3.8. The bacteri-
ophage titer was determined as described above using aliquots taken at 0, 30, and 60 min of incubation in SGF.
Alginate/CaCO3-encapsulated phage release in simulated intestinal fluid. Phage release from 
alginate capsules in SIF (pH 8.0), consisting of 1 mg pancreatin (Sigma-Aldrich, MO, USA)/ml, 10 mM bile salts, 
and 0.85% NaCl41, was determined. Thus, a suspension of alginate-encapsulated phages at a concentration of 
1 × 109 pfu/ml was inoculated in SIF and incubated in a water bath at 42 °C with agitation to emulate the condi-
tions of the avian intestine. Ctotal and Cfree were calculated as described above.
In vivo assays in broilers. Both the residence time in the chicken intestine and the effectiveness of a cock-
tail of alginate-encapsulated or non-encapsulated phages against Salmonella was evaluated in vivo in commer-
cial broilers (Gallus gallus, Ross strain 308; Terra-Avant S.A., Girona, Spain), using an experimental model that 
mimics farm conditions, as described in a previous study24. All in vivo animal experiments were performed in 
strict compliance with the protocols approved by the Comissió d’Ètica en l’Experimentació Animal i Humana 
(CEEAH) of the Universitat Autònoma de Barcelona (UAB). The approved study was assigned with the authori-
zation number 1953.
Caecum samples were collected from two euthanized chickens and tested using previously described enrich-
ment protocols24, to confirm that they were free of Salmonella and phages.
A curved oral-dosing needle was used to orally administer the broilers 100 μ l of a cocktail containing either 
the alginate-encapsulated or non-encapsulated phages24. The cocktail consisted of a 1:1:1 mixture of the three 
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phages (UAB_Phi20, UAB_Phi78, and UAB_Phi87) at a concentration of 1011 pfu/ml in MgSO4 buffer without 
antacid.
Bacteriophage retention in the chicken caecum. The intestinal residence time of the cocktail of either 
the encapsulated or non-encapsulated phages was determined over 72 h. Two independent experiments were 
conducted with two groups of 63 1-day-old chickens. The phage cocktail was administered at a dose of 1010 pfu/
animal as described previously24. After 2, 48, and 72 h, caecum samples were collected from 21 euthanized ani-
mals and processed as previously described24. The total phage number in the homogenized caecum samples was 
determined as described above. When direct detection of the phages was not possible, an enrichment procedure 
was carried out using a previously described method24.
Bacteriophage therapy. Bacteriophage therapy against Salmonella was evaluated over 17 days in chickens 
orally administered the different phage cocktails, as described in a previous work24. Briefly, the animals were 
orally infected on day 0 with a suspension of S. Typhimurium ATCC14028 RifR (107 cfu/animal). Three sequen-
tial experiments with groups of 84 commercial broilers (Gallus gallus, Ross strain 308) each were conducted. 
Group 1 corresponded to the Salmonella colonization control. Groups 2 and 3 received the non-encapsulated and 
alginate-encapsulated phages, respectively. In all cases, the oral dose of the three-phage cocktail (1010 pfu/animal) 
was administered once daily for 9 days (from day − 1 to day 7 after Salmonella infection). The control group was 
orally inoculated with MgSO4 (10 mM). To quantify the Salmonella and the phages, 14 chickens per group were 
euthanized on days 1, 3, 6, 8, 10, and 15 post-infection. Sample processing and determination of the Salmonella 
concentration in caecum samples were done as previously described24. The total concentration of bacteriophages 
was determined as described above. The reduction in the number of bacteria in each treatment was calculated by 
subtracting the mean caecal concentration (expressed in log 10 units) in groups 2 and 3 from the mean value of 
the control (group 1).
Statistical analysis. All results were analyzed using IBM SPSS software. For normally distributed samples, 
an analysis of variance (ANOVA) and Student’s t test were applied; in cases of a non-normal distribution, the 
Kruskal-Wallis and Mann-Whitney tests were used.
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